Research Area Treatment Experienced

A5415: A Limited-Center, Prospective, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living with HIV

People with HIV can have an increase in inflammation in their body organs even after taking anti-HIV medicines (ART, or…

Closed to accrual

24 weeks

See locations

A5385: An Observational Post-Intervention Cohort Destination Protocol

This study is a two-step, non-interventional extension study for individuals participating in another interventional HIV cure trial (parent study) that…

Open and enrolling

See locations

A5374: A Phase I/IIa Randomized, Placebo-Controlled Trial of Conserved-Mosaic T-cell Vaccine in a Regimen with Vesatolimod and Broadly Neutralizing Antibodies in Adults Initiated on Suppressive Antiretroviral Therapy during Acute HIV-1

Current antiretroviral therapy (ART) does not cure HIV. ART just holds the virus in check so it cannot multiply and…

Open and enrolling

Up to approximately 110 weeks depending on the time spent in Part 2 of the study.

See locations

A5403: Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study

Transgender women (TW) are the fastest-growing group of people with HIV. Historically, TW have had few opportunities to participate in…

Open and enrolling

Participants will complete about seven (7) visits over the course of 1 year.

See locations

A5321: Decay of HIV-1 Reservoirs in Participants on Long-Term Antiretroviral Therapy: The ACTG HIV Reservoirs Cohort (AHRC) Study

AHRC (pronounced “ARC”) is a study of differences and changes over time in HIV reservoirs (groups of HIV-infected cells that…

Open and enrolling

Participants will be expected to stay in the study for about 7 years.

 

See locations